Therapeutics on target:
Attacking cancer at the source™
About Us
PanTher Therapeutics is a clinical-stage oncology company revolutionizing cancer care by harnessing sustained treatments engineered for localized applications. We are bringing the fight against cancer precisely to the target with our proprietary treatment platform, Sagittari™, designed to enhance therapeutic response with minimal side effects.
Targeted Therapy Reimagined
At the core of PanTher’s approach is the ability to provide targeted, sustained, localized treatment, a property that enables more of the drug to reach and be retained at the tumor site.
Sagittari™ Platform
Our innovative Sagittari™ platform enables us to engineer optimized therapeutic solutions to address the specific challenges dictated by tumor type, location, and ideal therapeutic regimen.
Pancreatic cancer and beyond
Our lead candidate, PTM-101, is a minimally invasive, implantable treatment for pancreatic cancer that provides direct, sustained release of the therapeutic agent at the tumor site. It is currently being evaluated in a Phase 1 clinical trial as first line therapy for localized non-metastatic pancreatic cancers.
For Partners
We are building a pipeline of Sagittari™ platform product candidates and actively evaluating co-development opportunities that leverage our targeted approach to address the highest unmet medical needs in oncology.
Learn more about our Sagittari™ platform and our growing pipeline
PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
